Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT
Not Applicable
Recruiting
- Conditions
- Leukemia
- Interventions
- Procedure: Lymphoplasma exchange
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT06177561
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Follow-up Study of Autologous Transplantation of P63+ Lung Progenitor Cells for Treatment of Bronchiectasis
Not Applicable
Completed
- Conditions
- Bronchiectasis
- Interventions
- Other: RNA sequencing is performed on the remaining LPCsOther: Immunofluorescence staining is performed in the surgically resected lung tissue sections
- First Posted Date
- 2023-12-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 12
- Registration Number
- NCT06164093
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Clinical Research on Shenfu Injection in Septic Patients
Not Applicable
Recruiting
- Conditions
- Sepsis
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT06157320
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Characteristics of Intestinal Bacteria and Their Effects on Growth and Immune Function in Children at High Altitude
Recruiting
- Conditions
- HealthChildren, OnlyGut Microbiota
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06157346
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Famitinib in Combination With Adebrelimab for the Treatment of Advanced Thyroid Cancer
Phase 2
Not yet recruiting
- Conditions
- Thyroid Cancer
- Interventions
- Combination Product: 20 mg Famitinib & 1200 mg Adebrelimab
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT06146985
A Real-World Study to Evaluate the Clinical Performance and Safety of da Vinci SP Surgical System for Single-Port Colorectal Surgeries（SPiM-RWS-CR）
Completed
- Conditions
- Single-Port Colorectal Surgeries
- Interventions
- Procedure: procedure
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06141421
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Risk Factors and Outcomes in Coronary Chronic Total Occlusion
Recruiting
- Conditions
- Coronary Artery DiseaseChronic Total Occlusion
- Interventions
- Procedure: Coronary angiography
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 3000
- Registration Number
- NCT06137521
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2
Recruiting
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT06136351
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Organ Protective Effect of Cetirizine In Patients With Severe Burns
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06126991
- Locations
- 🇨🇳
Department of Burn, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06122493
- Locations
- 🇨🇳
Ruijin hospital, Shanghai jiaotong university school of medicine, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath